MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

EZH1/2

Search medical newsFind research, conditions and clinical updates
  • Home
  • EZH1/2
Targeting Leukemic Stem Cells in AML: Overcoming PI3K Inhibitor Resistance through Epigenetic Modulation
Posted inHematology-Oncology news Oncology

Targeting Leukemic Stem Cells in AML: Overcoming PI3K Inhibitor Resistance through Epigenetic Modulation

Posted by By MedXY 10/08/2026
This article explores novel therapeutic strategies in acute myeloid leukemia by combining PI3K inhibitors with EZH1/2 dual inhibitors to overcome epigenetic resistance mechanisms in leukemic stem cells, offering promising pathways to prevent relapse.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Why Plain Water Can Be Dangerous for Babies: The Science Behind Infant Water Intoxication
  • Is Infidelity Just “Zero Times or Countless Times”? Scientists Tracked 484 People and Found It’s Not That Simple
  • Why 130/80 mmHg Is No Longer “Close to Normal” Under the 2026 Global Blood Pressure Guidelines
  • Oral AR1001 Hits Primary Endpoint in Prespecified Early AD Monotherapy Cohort at CTAD 2026
  • Navigating the Ethical Crossroads of Prenatal Testing for Adult-Onset Genetic Conditions: The Case of Huntington Disease
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top